Anigen "Peptide Anticancer Carrier, Platform Technology Applicable to All Anticancer Drugs... Solubility Improved 10 Times"

Gwangju Institute of Science and Technology and 3 Innovative New Drug Joint Research and Development Applications

[Asia Economy Reporter Hyungsoo Park] Anigen announced on the 15th that it has filed a patent claiming domestic or overseas priority rights for an innovative new drug treatment under joint research and development with Gwangju Institute of Science and Technology.

Anigen, a peptide bio-material specialized company, is developing three pipelines: ▲ a novel peptide anticancer carrier targeting Nucleolin ▲ a peptide antibiotic for treating multidrug-resistant super bacteria ▲ a GPCR-targeting peptide metabolic disease treatment for diabetes and obesity.

Anigen has been steadily conducting joint research on innovative new drugs with Gwangju Institute of Science and Technology for over 10 years. Some of the research results have been filed as intellectual property patents. Currently, Anigen is proceeding with technology transfer of the patents from Gwangju Institute of Science and Technology for sole ownership and commercialization.

The patent for the novel peptide anticancer carrier targeting Nucleolin is a platform technology applicable to all currently used anticancer drugs. In particular, it improves the water solubility of poorly water-soluble anticancer drugs by more than 10 times and enhances drug targeting specificity to cancer cells, minimizing various side effects occurring in anticancer treatment.

The patent for the peptide antibiotic for treating multidrug-resistant super bacteria has a selective bacterial membrane destruction mechanism that kills infection-causing super bacteria in the human body within a short time. It is expected to be used as a treatment for various severe infectious diseases such as pneumonia and sepsis, for which there are currently no special treatments.

The patent for the GPCR-targeting peptide metabolic disease treatment for diabetes and obesity selectively acts on a specific orphan-GPCR whose ligand has not been known until now. It includes technical details on the development of a novel peptide ligand and a new metabolic disease platform drug applicable to the treatment of various metabolic diseases such as diabetes and obesity. Anigen plans to enter non-clinical research on the patent in the second half of this year.

Anigen produces medical, research, and cosmetic peptides (APIs) based on its proprietary peptide synthesis technology. It provides contract manufacturing (CMO) for new drug clinical trials to domestic and international pharmaceutical companies and bio venture companies. On December 9 last year, Anigen was selected as one of the 'Top 100 Small and Medium Materials, Parts, and Equipment Companies' by the Ministry of SMEs and Startups.

Anigen is the only company related to pharmaceuticals and bio in the basic chemical field. Selected companies in the Top 100 receive up to 18.2 billion KRW over five years to support the entire cycle including R&D, venture investment, commercialization funds, research personnel, export, and marketing to achieve rapid technological innovation and commercialization results.

Jaeil Kim, CEO of Anigen, explained, "We plan to focus all efforts on peptide active pharmaceutical ingredient production, new drug clinical contract manufacturing, and innovative new drug development," adding, "Osong Peptide Farm plans to obtain EU-GMP and US cGMP approvals in the future."

He continued, "Anigen will evolve from being the only GMP-certified peptide specialized company in Korea to a global peptide specialized company that mass-produces peptide APIs and clinical trial peptides (CMO) for new drug development and develops innovative peptide new drugs," expressing his ambition.

This content was produced with the assistance of AI translation services.